Targeting glycans for cancer immunotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41402488.
- Also identified by DOI 10.1038/s41587-025-02924-1 and PMC identifier 13045667.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Antibody–lectin chimeras (AbLecs) are an immunotherapy modality designed to bind and block glycans that contribute to immune suppression in cancer. AbLecs enhance antitumor immune responses both in vitro and in vivo, outperforming conventional antibody therapies, including approved cancer drugs.